Our resource hub is home to a wealth of articles, stories and videos about managing and living with type 1 diabetes.
Place your order for our free information packs that support adults and children who have been recently diagnosed.
Our researchers are working on different ways to develop a cure for type 1 diabetes - from growing insulin-producing beta cells in labs to hacking the immune system.
Learn about the technologies that can deliver insulin automatically when needed. And discover the next generation of insulins that are currently being developed.
You could win a cash prize of up to £25,000 when you play the JDRF lottery. As well as the chance to win great prizes, you’ll also help fund our research to find a cure for type 1 diabetes.
Your donations help support people living with type 1 diabetes today and fund the best treatment and cure research, no matter where in the world it takes place.
The announcement is the biggest treatment breakthrough for type 1 diabetes since the discovery of insulin.
The focus of this event is ‘type 1 technology’ covering aspects such as access, choice, and everyday living with type 1 technology.
We provide a wealth of information and free resources to help you support and empower your patients or students.
Take our free course for schools to learn more about supporting pupils with type 1 diabetes in educational settings.
Home > News & events > News > Hybrid closed loop likely to be recommended for over 100,000 people with type 1 diabetes
Draft guidance has been published which recommends that the NHS fund hybrid closed loop (HCL) systems, following years of dedicated research and campaigning by JDRF. The guidance will help more people access HCL, which helps relieve the burden of type 1 diabetes by automating insulin delivery.
The National Institute for Health and Care Excellence (NICE, the body which advises the NHS on treatments and technologies) has opened a public consultation on the draft guidance before it comes into force later this year.
If approved, it would mean over 100,000 people in England and Wales would qualify for NHS funding of HCL technology.
Hybrid closed loop is a sophisticated technology which uses an algorithm to link a user’s continuous glucose monitor (CGM) with their insulin pump to automatically deliver insulin.
Our Policy and Communications Director, Hilary Nathan, said, “Hybrid closed loop technology is a game-changing treatment at the forefront of health technology and artificial intelligence. HCL will transform the lives of people living with type 1 in England and Wales, reducing potentially fatal glucose highs and lows, lifting the relentless burden and reducing the risk of long-term complications such as sight loss, cardiovascular disease and kidney failure.”
This intelligent HCL technology was developed thanks to rigorous JDRF-funded research and clinical trials over almost 20 years, along with tireless campaigning and advocacy work by JDRF to make it available on the NHS.
The draft proposal recommends that the NHS offer HCL systems as an option for managing blood glucose levels for people with type 1 who are pregnant, planning a pregnancy, or have difficulty managing their condition (shown by an average HbA1c of around 8% (64 mmol/mol) or above).
The proposed guidelines say that anyone eligible for HCL will need the support of a trained team who have experience with insulin pumps and CGMs to receive an HCL system. People with type 1 must also attend a structured type 1 diabetes education programme to be eligible to receive HCL on the NHS.
This proposal document by NICE covers England and Wales. Scotland is already providing HCL systems to people with type 1 who need support managing their condition. We are pushing for people in Northern Ireland to have access to this crucial technology as soon as possible.
Once the consultation closes on 31st January, NICE will review the feedback and finalise the guidance. In the meantime, the NHS need to negotiate a cost-effective price before HCL is offered to patients.
Our passionate policy team and type 1 technology experts are drafting a comprehensive response to the proposed guidelines from NICE. In this feedback, we will include concerns and praise from the type 1 community as well as our own evidence-based comments.
NICE welcome comments from the public about their proposed guidelines. If you would like to contribute, add your views to this version of the hybrid closed loop proposal document by 5pm 31 January 2023.
The guidance committee would particularly like comments addressing these areas:
In an historic advancement in the treatment of type 1 diabetes, the National Institute for Health and Care Excellence (NICE) today approves hybrid closed loop for the majority of people living with type 1 diabetes in England and Wales.
As part of its assessment of hybrid closed loop (HCL), the National Institute for Health and Care Excellence (NICE) has today published an additional consultation on its roll out.
Insulet, the company who make Omnipod® products, has announced that their Omnipod® 5 hybrid closed loop (HCL) technology is now available in the UK.
Don’t miss out on the latest research, inspiring stories, tech news, upcoming events, and handy information on living well with type 1. Join us now and receive it all straight to your inbox.
It’s thanks to your dedication that we have funded great progress in type 1 cure, treatment and prevention research. Help us to continue our vital research.
